Researchers at the Emory/Georgia Tech Predictive Health Institute are bolstering the research behind vitamin D and improved heart health and blood pressure.
Researchers at the Emory/Georgia Tech Predictive Health Institute are bolstering the research behind vitamin D and improved heart health and blood pressure.
Emory cardiovascular researcher Ibhar Al Mheid, MD presented findings from a 554-subject trial on vitamin D and heart health at the American College of Cardiology meeting in New Orleans, which began last weekend. Al Mheid found that subjects who increased their vitamin D levels tended to improve vascular health and lower blood pressure.
“There is already a lot known about how vitamin D could be acting here,” said Al Mheid. “It could be strengthening endothelial cells and the muscles surrounding the blood vessels. It could also be reducing the level of angiotensin-a hormone that drives increased blood pressure-or regulating inflammation.”
Al Mheid’s team measured subject vitamin D status via 25-hydroxyvitamin D, a marker of dietary production and skin production of vitamin D. They concluded that 14% of subjects were vitamin D deficient and 33% of subjects were vitamin D insufficient.
Subjects who increased their vitamin D intake over a period of six months, either from dietary supplements or sun exposure, showed a trend towards improved heart health and lowered blood pressure. (Blood pressure was measured by inflating and removing blood pressure cuffs from the arms of subjects and measuring resulting blood flow changes with ultrasound.)
Subjects with unhealthy vitamin D levels were found to have stiffer arteries and poor blood function.
"We found that people with vitamin D deficiency had vascular dysfunction comparable to those with diabetes or hypertension," said Al Mheid.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.